Novel biomarkers for acute respiratory distress syndrome: Genetics, epigenetics and transcriptomics

25Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Acute respiratory distress syndrome (ARDS) can be induced by multiple clinical factors, including sepsis, acute pancreatitis, trauma, intestinal ischemia/reperfusion and burns. However, these factors alone may poorly explain the risk and outcomes of ARDS. Emerging evidence suggests that genomic-based or transcriptomic-based biomarkers may hold the promise to establish predictive or prognostic stratification methods for ARDS, and also to help in the development of novel therapeutic targets for ARDS. Notably, genetic/epigenetic variations correlated with susceptibility and prognosis of ARDS and circulating microRNAs have emerged as potential biomarkers for diagnosis or prognosis of ARDS. Although limited by sample size, ethnicity and phenotypic heterogeneity, ongoing genetic/transcriptomic research contributes to the characterization of novel biomarkers and ultimately helps to develop innovative therapeutics for ARDS patients.

Cite

CITATION STYLE

APA

Zheng, F., Pan, Y., Yang, Y., Zeng, C., Fang, X., Shu, Q., & Chen, Q. (2022, February 1). Novel biomarkers for acute respiratory distress syndrome: Genetics, epigenetics and transcriptomics. Biomarkers in Medicine. Newlands Press Ltd. https://doi.org/10.2217/bmm-2021-0749

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free